Lonza invests US$500 million for the construction of a new large-scale commercial drug product fill and finish facility in Stein (CH).
The new versatile facility will be built on the same campus as Lonza's current clinical medicinal product facility. This would enable the company to take advantage of the resources, people, and infrastructure already in place.
Customers will receive a complete and integrated end-to-end solution from the pharma facility, including commercial drug product manufacture for large-scale market supply.
The facility will adopt the most recent advancements in sustainable construction, using a cutting-edge strategy to reduce carbon emissions and use energy responsibly, including the installation of a photovoltaic roof.
The new building is anticipated to be completed in 2026.